The risk of metabolic syndrome in polycystic ovary syndrome: A systematic review and meta‐analysis

Behboudi‐Gandevani, Samira; Amiri, Mina; Yarandi, Razieh Bidhendi; Noroozzadeh, Mahsa; Farahmand, Maryam; Dovom, Marzieh Rostami; Tehrani, Fahimeh Ramezani

doi:10.1111/cen.13477

Cited by 69 publications

(44 citation statements)

References 79 publications

(410 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar opinion was expressed by Glintborg and Andersen, who suggested that prospective screening of lipids and BP is not necessary in normal‐weight patients with no metabolic risk factors until after the age of 35 to 40, as it appears that also the risk of AH in PCOS is closely associated with BMI . On the other hand, Behboudi‐Gandevani et al in a systematic review of 44 articles demonstrated that adolescents with PCOS had 2.5‐fold higher odds of MetS compared with controls, regardless of age, BMI, and recruitment sources of samples, whereas there were found no differences between adults with PCOS and controls . Accordingly, routine screening for components of metabolic syndrome is suggested for all women with PCOS, whereas the intervals for subsequent follow can be debated.…”

Section: Discussionmentioning

confidence: 67%

“…Behboudi-Gandevani et al in a systematic review of 44 articles demonstrated that adolescents with PCOS had 2.5-fold higher odds of MetS compared with controls, regardless of age, BMI, and recruitment sources of samples, whereas there were found no differences between adults with PCOS and controls. 133 Accordingly, routine screening for components of metabolic syndrome is suggested for all women with PCOS, whereas the intervals for subsequent follow can be debated.…”

Section: Cerebrovascular Diseasementioning

confidence: 99%

See 1 more Smart Citation

Polycystic ovary syndrome and the risk of cardiometabolic complications in longitudinal studies

Jacewicz-Święcka

Kowalska

2018

Diabetes Metabolism Res

View full text Add to dashboard Cite

The purpose of this study was to perform a review of the longitudinal studies to determine whether polycystic ovary syndrome is associated with higher prevalence of metabolic complications and cardiovascular morbidity and mortality. The primary outcomes included body mass index, metabolic syndrome and its components (waist circumference, lipid profile, arterial hypertension, abnormal glucose metabolism (impaired fasting glucose, impaired glucose tolerance, type 2 diabetes), insulin resistance, and cardiovascular diseases like stroke, angina, and coronary heart disease. Complications in pregnant women were beyond the scope of this review. PubMed database (1992-2018) was searched to identify proper publications. Finally, data from 47 articles were analysed. Studies differed in the design (prospective, retrospective, cohort, observational), research methods, polycystic ovary syndrome diagnostic criteria, studied populations, race, and ethnicity of the participants. Based on the data collected, it appears that women with polycystic ovary syndrome have higher prevalence of obesity, abdominal fat distribution, dyslipidaemia and deterioration of glucose metabolism, but increased prevalence of cardiovascular diseases is not proven.

show abstract

Section: Discussionmentioning

confidence: 67%

Section: Cerebrovascular Diseasementioning

confidence: 99%

Polycystic ovary syndrome and the risk of cardiometabolic complications in longitudinal studies

Jacewicz-Święcka

Kowalska

2018

Diabetes Metabolism Res

View full text Add to dashboard Cite

show abstract

“…Previous studies showed higher prevalence of MetS among women with PCOS in similar age groups, 17,18 ranging from 24% to 62% in women with overweight and obesity. [24][25][26] In two USbased studies, the prevalence of MetS in women with PCOS and BMI > 30 kg/m 2 was found to be 58.6%-61.8%.…”

Section: Discussionmentioning

confidence: 87%

“…13 In women with morbid obesity undergoing bariatric surgery, there was an even higher prevalence of PCOS. 18 Existing data regarding the prevalence of PCOS in women with severe obesity are contradictory; therefore, the primary aim of this study was to study the prevalence of PCOS among women with severe obesity (body mass index [BMI] ≥ 35.0 kg/m 2 ). 15,16 Women with PCOS, especially those with overweight or obesity, have a higher risk of developing MetS compared with a general population, 17 and this risk increases when using the NIH-diagnostic criteria compared to the Rotterdam consensus or androgen excess and PCOS Society criteria.…”

Section: Introductionmentioning

confidence: 99%

“…15,16 Women with PCOS, especially those with overweight or obesity, have a higher risk of developing MetS compared with a general population, 17 and this risk increases when using the NIH-diagnostic criteria compared to the Rotterdam consensus or androgen excess and PCOS Society criteria. 18 Existing data regarding the prevalence of PCOS in women with severe obesity are contradictory; therefore, the primary aim of this study was to study the prevalence of PCOS among women with severe obesity (body mass index [BMI] ≥ 35.0 kg/m 2 ). Secondary aims were to study the prevalence of MetS among women with severe obesity with and without PCOS, and to evaluate the effects of a 12-months structured weight loss programme on endocrine and metabolic variables.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of polycystic ovary syndrome in women with severe obesity – Effects of a structured weight loss programme

Kataoka

Larsson

Björkman

et al. 2019

Clinical Endocrinology

View full text Add to dashboard Cite

Objective: Existing data are contradictory on the prevalence of polycystic ovary syndrome (PCOS) and metabolic syndrome (MetS) in women with severe obesity (body mass index [BMI] ≥ 35 kg/m 2 ), and there are few studies investigating the effect of weight reduction in women with severe obesity and PCOS. The aim was to study the prevalence of PCOS and MetS among women with severe obesity and to evaluate the effect of a 12-months weight loss programme on the prevalence of PCOS and MetS. Design/Participants: In total, 298 women with severe obesity were enrolled whereof 246 women had complete screening data for PCOS and MetS before commencing treatment. Weight loss intervention included very low energy diet. At 12-months follow-up, 72 women with complete data remained and were re-examined with baseline parameters.Results: At baseline, the prevalence of PCOS was 25.6% and in this group, the prevalence of MetS was 43.4% in PCOS vs 43.3% in controls (ns). At 12-months follow-up, weight loss in women with PCOS was 12.3 ± 10.7 kg (P < .001) and in non-PCOS 13.9 ± 13.4 kg (P < .001) with no between group difference. Women without PCOS decreased in total bone mass. Conclusions:Polycystic ovary syndrome occurs in one out of four women with severe obesity. The prevalence of MetS does not differ between women with or without PCOS with severe obesity. There was a significant weight loss in both groups but no difference between groups regarding change in metabolic parameters. K E Y W O R D Shyperandrogenemia, lipids, metabolic syndrome, polycystic ovary syndrome diagnosis, prevalence, severe obesity, weight loss treatment | 751 KATAOKA eT Al.

show abstract

Polycystic Ovarian Syndrome (PCOS)

Golub

Cantor

Smith

2020

Adolescent Nutrition

View full text Add to dashboard Cite

The risk of metabolic syndrome in polycystic ovary syndrome: A systematic review and meta‐analysis

Abstract: SummaryBackground and Objective: Polycystic ovary syndrome (PCOS) is a common heteroge-

Cited by 69 publications

References 79 publications

Polycystic ovary syndrome and the risk of cardiometabolic complications in longitudinal studies

Polycystic ovary syndrome and the risk of cardiometabolic complications in longitudinal studies

Prevalence of polycystic ovary syndrome in women with severe obesity – Effects of a structured weight loss programme

Polycystic Ovarian Syndrome (PCOS)

Contact Info

Product

Resources

About